OBR Daily Commentary

forumImage

Neoadjuvant Combination Immunotherapy Improves Outcomes For Early Stage Non-small Cell Lung Cancer

(MD Anderson) Feb 18, 2021 - The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine.

Read Article arrow

H. Jack West, MD (Posted: February 20, 2021)

quotesThough there is a lot of focus on neoadjuvant immunotherapy for lung cancer, many if not most practicing oncologists will be seeking more established endpoints like a significant improvement in overall survival, or at least disease-free survival, rather than focusing on relatively newer variables like major pathological response that have been "retrofitted" as an endpoint of choice because they show a benefit quickly. Neoadjuvant immunotherapy or chemoimmunotherapy should generate great enthusiasm and become a new standard of care if and when it produces improvements in established endpoints in prospective, randomized phase 3 trials -- not before that. Immunologic endpoints don't counterbalance the side effects and costs of immunotherapy.quotes

Add Comment 1 Comment
forumImage

The Lancet Publishes Libtayo® (cemiplimab) Data Showing Extended Overall Survival in Patients With First-line Advanced Non-Small Cell Lung Cancer With PD-L1 Expression of ³50%

(Sanofi) Feb 12, 2021 - The Lancet today published results from a pivotal trial designed to evaluate the investigational use of the PD-1 inhibitor Libtayo® (cemiplimab) compared to platinum-doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression in tumor cells. The data were shared during a late-breaking presentation at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress and formed the basis of regulatory submissions in the U.S. and European Union (EU). The U.S. Food and Drug Administration (FDA) granted a Priority Review with a target action date of February 28, 2021. A European Commission decision is expected by mid-2021.

Read Article arrow

H. Jack West, MD (Posted: February 12, 2021)

quotesAs the third entrant in the same clinical setting to show a survival benefit over a quite outdated comparator arm of chemotherapy alone, cemiplimab fails to demonstrate any meaningful incremental benefit over pembrolizumab as the current standard of care in this setting or atezolizumab as a similarly active but already arguably redundant alternative here. I strongly suspect that clinicians will not see a compelling reason to change their current preference in this setting, absent a marked cost difference in favor of cemiplimab to offer a point of differentiation.quotes

Add Comment 1 Comment
forumImage

FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations

(Merck KGaA) Feb 3, 2021 - Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has approved TEPMETKO® (tepotinib) following Priority Review for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Read Article arrow

H. Jack West, MD (Posted: February 04, 2021)

quotesIt's good to get another approval in NSCLC, and tepotinib has high efficacy and generally very good tolerability in MET exon 14 skipping mutation-positive NSCLC, but this is also a setting in which we already have capmatinib, which has very similar efficacy and tolerability. There are a small fraction of patients who can't tolerate one but may do better with another, but I must confess that the utility of a second agent in the same space offers limited incremental benefit, at least unless we learn that patients can respond to one after progressing on the other, which I would suspect is not the case.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...